Related Experiment Video
Updated: Aug 29, 2026
Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis
Published on: September 9, 2014
[Effects of recombinant human erythropoietin on the immune function of premature rats]
Hui-ling Tu1, Hong-mao Ye, Jun Wang
1Department of Pediatrics, Third Hospital, Peking University, Beijing 100083, China.
Insights
Recombinant human erythropoietin (rHuEPO) improved red blood cell immune function, T cell responsiveness, and tumor necrosis factor-alpha production in premature rats. Higher rHuEPO doses showed more significant positive effects on these immune markers.
Area of Science:
- Immunology
- Neonatal Research
- Pharmacology
Background:
- Premature neonates exhibit underdeveloped immune systems, characterized by lower red blood cell (RBC) immune function, T lymphocyte responsiveness, and tumor necrosis factor-alpha (TNF-alpha) production compared to mature neonates.
- This compromised immune status increases vulnerability to infections and complications in premature infants.
Purpose of the Study:
- To investigate the impact of recombinant human erythropoietin (rHuEPO) administration on the immune function of premature rats.
- To assess the dose-dependent effects of rHuEPO on key immunological parameters.
Main Methods:
- Premature rats were administered varying doses of rHuEPO (250 IU/kg or 500 IU/kg) or normal saline (control) every other day for 19 days.
- Evaluated parameters included hemoglobin (Hb), serum erythropoietin (EPO), RBC immune function (C3b-R%, IC-R%), T lymphocyte proliferative responsiveness (OD index), and TNF-alpha production.
Main Results:
- rHuEPO treatment significantly improved Hb levels, RBC immune function, T cell responsiveness, and TNF-alpha production in premature rats compared to controls.
- The higher rHuEPO dosage (500 IU/kg) demonstrated more pronounced improvements in these immune markers than the lower dosage (250 IU/kg).
- Specifically, Hb increased from 7.72 g/dl in controls to 10.08 g/dl with 500 IU/kg rHuEPO; C3b-R% increased from 11.00% to 17.75%; and TNF-alpha increased from 0.270 ng/ml to 0.415 ng/ml (all P < 0.01).
Conclusions:
- Premature rats exhibit inherent deficits in RBC immune function, T cell responsiveness, and TNF-alpha production at birth.
- rHuEPO administration effectively enhances RBC immune function, T cell responsiveness, and TNF-alpha production in premature rats.
- A positive correlation exists between improved RBC immune function, T cell responsiveness, and enhanced TNF-alpha production following rHuEPO treatment.
Objective:
To observe the effect of recombinant human erythropoietin (rHuEPO) on immune function of premature rats.
Methods:
RHuEPO of 250 IU/(kg.t) or 500 IU/(kg.t) was administered to premature rats every other day for nineteen days. The control premature rats were received normal saline. The changes of hemoglobin (Hb), serum erythropoietin (EPO), red blood cell (RBC) immune function, T lymphocyte proliferative responsiveness, and production of tumor necrosis factor alpha (TNF-alpha) were observed.
Results:
Premature rats showed lower levels on Hb, RBC immune function, T cell responsiveness and production of TNF-alpha compared with mature rats at birth. The postnatal declines of Hb and RBC immune function were lessened in the treated groups of premature rats, the higher dosage group of 500 IU/(kg.t) was more significant than the lower dosage group of 250 IU/(kg.t). When experiments were over, Hb of control premature rats was (7.72 +/- 0.89) g/dl, Hb of premature rats received 500 IU/(kg.t) was (10.08 +/- 0.90) g/dl (P < 0.01). C3b-R% of control premature rats was (11.00 +/- 0.95)%, C3b-R% of premature rats received 500 IU/(kg.t) was (17.75 +/- 1.04)% (P < 0.01). IC-R% in control premature rats was (12.83 +/- 1.33)%, IC-R% of premature rats received 500 IU/(kg.t) was (10.50 +/- 1.67)% (P < 0.01). The postnatal rise of T cell responsiveness and the production of TNF-alpha in premature rats increased in the treated groups, which was more significant in the higher dosage group of 500 IU/(kg.t) than in the lower dosage group of 250 IU/(kg.t). The OD index of control premature rats was 0.159 +/- 0.014, the OD index of premature rats received 500 IU/(kg.t) was 0.354 +/- 0.050 (P < 0.01). TNF-alpha in control premature rats was (0.270 +/- 0.014) ng/ml, TNF-alpha of premature rats received 500 IU/(kg.t) was (0.415 +/- 0.010) ng/ml (P < 0.01).
Conclusions:
(1) Premature rats had lower RBC immune function and T cell responsiveness and underproduction of TNF-alpha at birth. (2) Premature rats had an improvement with the RBC immune function after rHuEPO administration. (3) Premature rats had improvements with T cell responsiveness and TNF-alpha after rHuEPO administration, and there was a positive correction between the RBC immune function and T cell responsiveness with the production of TNF-alpha.
